Event Participants
Executives
3
Arvind Agrawal, Rajesh Agrawal, Yogesh Agrawal
Analysts
10
Abdulkader Puranwala, Anupam Agarwal, Bino Pathiparambil, Foram Parekh, Kavya Shah, Pankaj Shah, Pankaj Tibrewal, Rashmi Shetty, Tushar Manudhane, Yogesh Soni
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Total Revenue from Operations | ₹1,626 crores | +25% YoY vs ₹1,303 crores; broad-based growth across India (+24%), US (+57%), Africa branded (+30%), and Africa institutional (+71%), partially offset by Asia (-16%) |
| India Business Sales | ₹509 crores | +24% YoY vs ₹409 crores; 32% of revenue; trade generics at ₹48 crores vs ₹39 crores; IQVIA MAT growth 15% vs IPM 11%; three-month IQVIA run-rate ~18% |
| US Generics Sales | ₹487 crores | +57% YoY vs ₹310 crores; 30% of revenue; two product launches in Q1; growth expected to normalize as competition/price erosion set in |
| Africa Branded Sales | ₹295 crores | +30% YoY vs ₹228 crores; three launches in the quarter; market growing 7–12%, Ajanta outpacing it meaningfully |
| Asia Branded Sales | ₹225 crores | -16% YoY vs ₹304 crores; Middle East geopolitical supply chain disruption; some Q1 dispatches pushed to Q2 |
| Africa Institutional Sales | ₹49 crores | +71% YoY vs ₹28 crores; ~4% of revenue; volatile but guided high double-digit for the year |
| Gross Margin | 80% | +100 bps QoQ vs Q4 FY26; full-year guidance ~78% ±100 bps |
| Adjusted EBITDA (excl. FX loss) | ₹454 crores | +21% YoY vs ₹371 crores; margin 28%; full-year guidance ~27% ±100 bps |
| Profit After Tax | ₹334 crores | +31% YoY vs ₹255 crores; effective tax rate 25% for Q1, ~26% guided for FY27 |
| Personnel Cost | ₹381 crores | +26% YoY vs ₹303 crores; +12% QoQ on annual increments and ~50 international MR additions |
| Other Expenses | ₹493 crores | +32% YoY vs ₹373 crores; +11% QoQ; continued investment in products, brands, and people |
| R&D Spend | ₹66 crores | ~4% of revenue vs ₹56 crores; FY27 guided at ~5% of revenue |
| Capex (Q1) | ₹83 crores | FY27 guidance ~₹400 crores; ~₹100 crores maintenance + ~₹300 crores Pithampur expansion |
| ROCE / RONW | 37% / 28% | As of June 30, 2026 |
| Interim Dividend | ₹32 per share | On face value ₹2; total payout ~₹400 crores |
Geographic & Segment Commentary
India Branded: Sales grew 24% YoY to ₹509 crores with eight new product launches; IQVIA MAT growth of 15% versus IPM's 11%, with volume growth 40% higher than the market and new launches beating the market by 75%. Segment mix: cardiology 37%, ophthalmology 29%, dermatology 22%, pain management 10%, new therapeutic areas 2%; company is top-10 in every core therapy segment.
US Generics: Sales up 57% YoY to ₹487 crores (30% of revenue), driven by momentum from FY26 and two Q1 launches. Management expects competition-led price erosion and market share loss to normalize growth to mid-single digits; no launches in Q2/Q3, most launches weighted to Q4 subject to FDA approvals. Market share exceeds 20% in most products.
Asia Branded: Sales declined 16% YoY to ₹225 crores on continued Middle East geopolitical disruption to supply chains and logistics; three products launched. Management expects Q2 to be elevated as delayed Q1 dispatches get booked, with demand intact and mid-to-high teens full-year guidance maintained.
Africa Branded: Sales grew 30% YoY to ₹295 crores with three launches; the 2–3 year field-force ramp-up is now turning productive, driving growth well above the 7–12% market growth. High double-digit growth guided for the full year.
Africa Institutional: Sales grew 71% YoY to ₹49 crores (~4% of revenue), in line with expectations; high double-digit growth guidance maintained for FY27 despite inherent quarterly volatility.
Company-Specific & Strategic Commentary
Product Pipeline & US Filings: 5–7 US filings planned in FY27; launches are FDA-dependent and heavily skewed to Q4. Most current US sales still come from the existing portfolio, with recent launches yet to contribute meaningfully.
Field Force Expansion: ~50 international MRs added in Q1 (total ~6,000); India field-force investments made over the past two years are now contributing to volume-led outperformance, and the Africa field-force expansion is driving above-market growth.
Capacity Expansion: FY27 capex guided at ~₹400 crores — ~₹100 crores maintenance and ~₹300 crores toward Pithampur plant expansion for emerging markets.
New Geographies: Asia, Middle East, and Latin America are at the drawing-board stage with product selection and filings; contributions expected over a 3–5 year horizon.
Capital Returns: Board approved interim dividend of ₹32 per share (~₹400 crores total payout), reaffirming capital return commitment.
Semaglutide: India offtake has plateaued (market ARR MAT ~₹850 crores), below industry expectations, though brand-share gains remain possible; Asia/Africa entry is still two-plus years away and management cites strong cardio-diabetes equity as the basis for optimism.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Overall Revenue Growth | High teens, FY27 | Reaffirmed; diversified geography mix cushions regional shocks |
| India Business Growth | Mid-teens, FY27 | Volume (4.7% MAT vs 3.4% market) and new launches are key drivers; prices roughly in line with IPM |
| US Generics Growth | Mid-single to upper mid-single digit, FY27 | Q1 was elevated (57%); new competition and price erosion factored in for H2; launch concentration in Q4 |
| Asia Branded Growth | Mid-to-high teens, FY27 | Q2 recovery expected with delayed Q1 dispatches realized; logistics being resolved, demand intact |
| Africa Branded Growth | High double digit, FY27 | Supported by productive field force and launches; market grows 7–12% |
| Africa Institutional Growth | High double digit, FY27 | Momentum expected to continue despite quarterly volatility |
| Gross Margin | ~78% ±100 bps, FY27 | Q1 at 80%; expected moderation from US price erosion and product mix |
| EBITDA Margin (excl. FX) | ~27% ±100 bps, FY27 | Continued investment in people, brands, and products |
| R&D Spend | ~5% of revenue, FY27 | Q1 at ~4%; higher filings/development in pipeline |
| Capex | ~₹400 crores, FY27 | ₹300 crores Pithampur expansion + ₹100 crores maintenance |
| Effective Tax Rate | ~26%, FY27 | Q1 at 25% |
| US Filings | 5–7 filings, FY27 | Actual launches depend on FDA approval timing, mostly Q4 |
Risks & Constraints
| Risk | Context |
|---|---|
| Middle East Geopolitical Disruptions | Supply chain issues caused Asia sales to fall 16% YoY in Q1; demand is intact but logistics remain the bottleneck. Management is "reasonably confident" of Q2 recovery, but any further escalation could push sales realization further out |
| US Competition & Price Erosion | Q1 US growth of 57% is expected to taper to mid-single digits; management has factored in new competition, share loss, and price erosion in H2, but the quantum is unquantified |
| US Tariff Policy Uncertainty | Generics are exempt from Section 232 tariffs till April 2027; a new study with a two-year (August 28) timeline has been announced. Management is monitoring closely, but tariff risk beyond the exemption window remains |
| Raw Material Inflation | Geopolitical tensions have triggered raw material cost discussions; no Q1 impact due to inventory buffer, but some impact is possible from Q2 onward |
| FDA Approval Timing | Launch pipeline (including Q4 launches) is approval-dependent; delays could shift US growth contribution and the guided 5–7 filings |
| Asia Supply Chain Execution | Alternate routes are being arranged; management has visibility on shipments, but repeated push-outs remain a watch item for the mid-to-high teens Asia guidance |
Q&A Highlights
India Growth vs IQVIA
- Question: Why does reported India growth (~24–25%) diverge from IQVIA MAT growth of 15%? (Tushar Manudhane)
- Answer: IQVIA MAT is a rolling figure; on a three-month basis, Ajanta is growing ~18% vs IPM ~11%. Some divergence between IQVIA capture and internal numbers is normal. In cardiology specifically, IQVIA capture has been inaccurate, and management has been engaging with IQVIA for the past three quarters to align stockist coverage (Rajesh Agrawal).
Asia Recovery Path
- Question: Can Asia scale from a ₹255 crore run-rate to ~₹350 crore per quarter needed for mid-teens growth? (Tushar Manudhane, Rashmi Shetty, Foram Parekh)
- Answer: Some Q1 sales were delayed in transit and will be realized in Q2; demand generation is not the constraint, only logistics. Alternate supply routes are being set up, and management is "reasonably confident" of delivering mid-to-high teens for the full year (Yogesh Agrawal).
Semaglutide Expectations
- Question: India semaglutide uptake is below industry anticipation; does this change Asia/Africa strategy? (Tushar Manudhane)
- Answer: The India market has plateaued with ARR MAT around ₹850 crores, below industry expectations, though still a large market where brand-share gains are possible. Asia/Africa launches are two-plus years away, so it is too early to assess; Ajanta's cardio-diabetics equity keeps management optimistic (Rajesh Agrawal).
India Growth Composition & FY27 Guidance
- Question: Which therapies and growth components (price vs volume) drove the 24% India growth? (Rashmi Shetty)
- Answer: Growth is broad-based — ophthalmology is growing at 1.3x the market, dermatology and pain faster, cardiology at par or better. Volume growth is 4.7% MAT vs 3.4% for the market; price is roughly in line with IPM; volume and new launches are the key drivers. India guidance remains mid-teens (Rajesh Agrawal).
Africa Branded Outperformance
- Question: What is the Africa pharma market growth, and why is Ajanta growing faster? (Rashmi Shetty)
- Answer: The market grows ~7–12% YoY; Ajanta's growth is much higher, driven by a large field force built over the last 2–3 years now turning productive, new launches, and strong brand equity. High double-digit guidance is maintained for FY27 (Yogesh Agrawal).
US Growth Normalization & Launch Cadence
- Question: How should we read the US after a 57% Q1, and what is the launch pipeline? (Pankaj Tibrewal, Kavya Shah, Foram Parekh)
- Answer: Q1 momentum is a carryover from FY26's strong quarters; guidance remains mid-single to upper mid-single digit as competition and price erosion are factored in for H2. Two launches happened in Q1; no launches in Q2/Q3; most are expected in Q4 subject to FDA approvals, with 5–7 filings planned in FY27 (Yogesh Agrawal).
US Tariff Study
- Question: Views on the US administration's new generic tariff study? (Anupam Agarwal)
- Answer: Generics are exempt from Section 232 tariffs till April 2027; a new study with a two-year (August 28) timeline has been announced, about six months beyond the current administration's term. There is uncertainty, but no immediate impact; management is closely monitoring developments (Yogesh Agrawal).
Gross Margin & Raw Material Costs
- Question: Q1 gross margin is 80% vs 78% guidance — is raw material inflation a concern? (Pankaj Shah, Abdulkader Puranwala)
- Answer: No major cost headwinds yet; gross margin should ease toward ~78% due to US price erosion and product mix. Raw material cost increase discussions are happening because of geopolitics, but inventory holdings protected Q1; some impact is possible from Q2 onward (Arvind Agrawal, Yogesh Agrawal).
Personnel Cost Increase
- Question: MR count is flat at ~6,000 but personnel cost is up; what is driving it? (Pankaj Shah)
- Answer: The QoQ increase is ~12%, largely annual increments; 50 international MRs were added in Q1 (Arvind Agrawal).
PCPM vs Peers
- Question: India PCPM of ~₹3.5–4 lakh vs peers at ~₹5 lakh — how should this be read? (Yogesh Soni)
- Answer: Not directly comparable because of different therapy mix — most peers do not operate in ophthalmology. Ajanta's Q1 PCPM is ~₹4.5 lakh; ophthalmology productivity is at par with the best, while newer segments (gynaecology, nephrology, ~18 months old) drag the blended number. Segment-wise comparison is needed (Rajesh Agrawal).
Medium-Term Growth Engines
- Question: After a 14% CAGR over the last three years, what accelerates growth going forward? (Pankaj Tibrewal)
- Answer: Four levers: new product filings/approvals (India, emerging markets, US) contributing 2–3% growth; market share gains in newer brands; new geographies (Asia, Middle East, Latin America) playing out over 3–5 years; and continued field-force additions/new divisions. Execution is supported by market tailwinds, but geopolitical and macro shocks remain outside management control (Yogesh Agrawal).
Key Takeaway
Ajanta Pharma opened FY27 with revenue from operations up 25% YoY to ₹1,626 crores and PAT up 31% to ₹334 crores, led by India (+24%), US (+57%), Africa branded (+30%), and Africa institutional (+71%), while Asia fell 16% on Middle East supply chain disruptions. Management reaffirmed high-teens total revenue growth, mid-teens India, mid-to-upper single-digit US, high double-digit Africa across branded and institutional, and mid-to-high teens Asia with Q2 carry-forward of delayed shipments. Gross margin at 80% and EBITDA margin at 28% ran ahead of full-year guides of ~78% and ~27% (±100 bps), with US price erosion and possible raw material inflation flagged as moderating factors. Strategic spends continue — ~₹400 crores capex (₹300 crores Pithampur expansion), 50 international MR additions, and 5–7 US filings — while semaglutide remains an option in emerging markets beyond FY27. Key watch items are US competition and tariff policy, Asia logistics resolution, and FDA approval timing shaping H2 launches.